18- Ilhan O, Ozcan M, Yalçın A, et al. Interferon alpha2a and low dose cytarabine in chronic myeloid leukemia: second interim analysis of multicenter study. Blood 1998, 92 (Suppl 2) 246: 4056a 19- Beelen DW, Graeven U, Elmaagaclı AH, et al. Prolonged administration of interferonalpha in patients with chronic phase Philedelphia chromosome positive chronic myelogeneous leukemia before Allogeneic bone marrow transplantation may adversely affect transplant outcome. Blood 1995, 85: 2981-2990 20- Morton AJ, Gooley T, Hansen JA, et al. Association between pretransplant interferonalpha and outcome after unrelated donor marrow transplantation of chronic myelogenous leukemia in chronic phase. Blood 1998, 92: 394-401 21- Beksac M, Celebi H, Sargın D, et al. Role of pretransplant interferon-alpha (IFN) treatment in the outcome of stem cell transplantation (SCT) from related donors in chronic myelogeneous leukemia (CML): results from three Turkish transplant centers. 22- Capdeville R and Silberman S. Imatinib: a targeted clinical drug development. Semin Hematol 2003, 40: 15-20 23- <strong>Dr</strong>uker BJ, Tamura S, Buncdunger E, et al. Effects of selective inhibitor of Abl tyrosine kinase on growth of BCR-ABL positive cells Nat Med 1996, 2: 561-566 24- <strong>Dr</strong>uker BJ, Talpaz M, Resta D, et al Efficacy and safety spesific inhibitor of the Bcr- Abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001, 344: 1031-1037 25- <strong>Dr</strong>uker BJ, Sawyer JL, Kantarjian H, et al. Activity of the specific inhibitor of the Bcr- Abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philedelphia chromosome. N Engl J Med, 2001 344: 1038-1042 26- <strong>Dr</strong>uker BJ. Imatinib Alone and in Combination for Chronic Myeloid Leukemia. Seminar Hematol 2003, 40: 50-58 27- Kantarjian H, Sawyer J, Hochhaus A, et al. hematologic and cytogenetic responses to imatinib mesylate in chronic myelogeneous leukemia. N Engl J Med 2002, 346: 645- 652 28- Talpaz M, Silver RT, <strong>Dr</strong>uker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study. Blood 2003, 1928-1937 29- Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogentic responses in patients with chronic myeloid leukemia in myeloid blast crisis: Results of phase II study. Blood 2002, 99: 3530-3539 30- <strong>Dr</strong>uker BJ, for the IRIS (International Randomized IFN vs STI571) Study Group: STI571 (Gleevec/Glivec, Imatinib) versus interferon (IFN) + Cytarabine as initial therapy for patients with CML: Results of a randomized study. Proc Am Soc Clin Onc 21: 1a, 2002 (abstr) 31- Goldman JM. Chronic myeloid leukemia-still a few questions. Exp Hematol 2004, 32: 2-10 32- Kantarjian H, Talpaz M, O’Brien S, et al. High-dose Imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2003, Dec (First Edition, prepublished online) 33- Grathwohl A. Prognostic factors in chronic myeloid leukemia allografting. Seminar Hematol 2003, 40:13-21 34- Van Rhee F, Szydlo RM, Hermans J ve ark. Leukemia WP of EBMT: Long term results after allogeneic bone marrow transplantation for CML in chronic phase. Bone Marrow Transplant 1997, 20:553
35- Passweg J, Walker I, Sobocinski K, et al. Validation of the EBMT risk score for recipients of allogeneic hematopoetic stem cell transplants for chronic myeloid leukemia (CML). Bone Marrow Transpl 2002, 29: S23 36- Hansen JA, Gooley TA, Martin PJ ve ark. Bone marrow transplants from unrelated donor for patients with chronic myeloid leukemia. N Engl J Med 338:962, 1998 37- Barret J. Allogeneic stem cell transplantation for chronic myeloid leukemia. Seminar Hematol 2003, 40: 59-71 38- Beksac M, Arat M, Dalva K, et al. Comparative analysis of molecular response following interpheron-alpha, imatinib mesilate or allogeneic stem cell transplantation (ASCT): best response is obtained with ASCT in chronic myeloid leukemia. Bone Marrow Transp 2003, 31 (suppl 1): S161
Change language